Table of contents
Pituitary carcinoma
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of pituitary carcinoma are prepared by our editorial team based on guidelines from the Acromegaly Consensus Conference (ACC 2018), the European Society of Endocrinology (ESE 2018), and the Endocrine Society (ES 2011).
1
2
3
Screening and diagnosis
Diagnostic investigations
Brain imaging: as per ESE 2018 guidelines, obtain imaging (MRI in most instances) for quantification of tumor dimensions, invasion, and growth.
E
More topics in this section
Imaging for staging
Laboratory testing
Genetic testing
Diagnostic procedures
Histopathology
As per ESE 2018 guidelines:
Obtain histopathological analysis, including a minimum immunodetection of pituitary hormones and Ki-67 proliferative index evaluation, in all patients with pituitary tumors. Obtain at least p53 immunodetection and mitotic count assessment when the Ki-67 index is ≥ 3%.
B
Interpret histopathological results in the clinical context of the individual patient.
B
Medical management
General principles
As per ESE 2018 guidelines:
Discuss patients with aggressive pituitary tumors and carcinomas in a multidisciplinary expert team meeting (including endocrinologists, neurosurgeons, pituitary pathologists, neuroradiologists, radiation oncologists, and medical oncologists).
E
Offer standard medical treatment with maximally tolerated doses in order to control tumor growth, as per current guidelines.
E
More topics in this section
Temozolomide
Other cytotoxic therapies
Therapeutic procedures
Radiotherapy: as per ESE 2018 guidelines, offer radiotherapy in patients with clinically relevant tumor growth despite surgery in nonfunctioning tumors or surgery and standard medical treatment in functioning tumors.
B
Show 2 more
More topics in this section
Locoregional therapies
Surgical interventions
Follow-up and surveillance
Assessment of treatment response: as per ESE 2018 guidelines, obtain careful clinical observation for potential adverse effects and monitor hematological parameters and LFTs during treatment.
B
Show 3 more
More topics in this section
Imaging and laboratory follow-up
Management of recurrence